News Releases

Date	Title and Summary	View
Dec 10, 2021	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Dec 10, 2021	Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® ▼ (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy
Dec 09, 2021	World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
Dec 09, 2021	Johnson & Johnson Appoints Senior Leaders to Executive Committee
Dec 05, 2021	Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
Dec 01, 2021	U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidasefihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Nov 24, 2021	Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older
Nov 23, 2021	European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults
Nov 15, 2021	Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Nov 12, 2021	Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business